ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P ASX 200
7,073.20
(
-0.2%
)
S&P ASX All Technology
2,475.10
(
-0.5%
)
Brent Oil
79.125
(
0.0%
)
US Dollar vs AUD
1.49993
(
0.0%
)
Bitcoin
39,570.47
(
0.24%
)
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Addex Therapeutics Ltd (ADXN)

  7. Addex Therapeutics Ltd (ADXN) News

ADXN Addex Therapeutics Ltd

5.78
0.23 (4.14%)
02 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Addex Therapeutics Ltd ADXN NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.23 4.14% 5.78 09:32:30
Open Price Low Price High Price Close Price Previous Close
5.79 5.52 5.80 5.78 5.55
more quote information »

Recent News

Date Time Source Heading
01/12/202308:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30/11/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
30/11/202308:00EDGAR2Form SC 13D/A - General statement of acquisition of..
29/11/202322:27EDGAR2Form POS AM - Post-Effective amendments for registration..
29/11/202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202317:00GLOBEAddex Reports Q3 2023 Financial Results and Provides..
28/11/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202317:00GLOBEAddex Convenes Extraordinary General Meeting
23/11/202317:00GLOBEAddex Therapeutics to Release Third Quarter 2023 Financial..
14/11/202317:00GLOBEAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment..
08/11/202322:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202317:00GLOBEAddex Regains Nasdaq Listing Compliance
02/11/202317:00GLOBEAddex Announces Participation in the Bio-Europe 2023..
23/10/202321:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/10/202321:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/10/202316:00GLOBEAddex Completes ADS Ratio Change
07/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/10/202307:00GLOBEAddex Announces Plan to Implement ADS Ratio Change
20/9/202320:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202315:00GLOBEAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
06/9/202315:00GLOBEAddex Announces Participation in the H.C. Wainwright 25th..
05/9/202320:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202320:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202315:00GLOBEAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout..
04/9/202315:00GLOBEAddex’s Dipraglurant Development in Post-Stroke Recovery..
12/8/202306:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
11/8/202306:00EDGAR2Form POS AM - Post-Effective amendments for registration..
10/8/202320:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202315:00GLOBEAddex Reports 2023 Half Year and Second Quarter Financial..
04/8/202315:00GLOBEAddex Therapeutics to Release Half-Year 2023 Financial..
03/8/202320:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202315:00GLOBEAddex GABAB Positive Allosteric Modulator Program to Receive..
24/7/202320:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202315:00GLOBEAddex mGlu2PAM Demonstrates Potential in Substance Use..
15/6/202315:00GLOBEAddex Increases Issued Share Capital to Create Treasury..
01/6/202315:00GLOBEAddex Shareholders Approve All Resolutions at Annual General..
18/5/202315:00GLOBEAddex Receives Nasdaq Notification Regarding Minimum Bid..
11/5/202315:00GLOBEAddex Reports Q1 2023 Financial Results and Provides..
10/5/202315:00GLOBEAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s..
05/5/202315:00GLOBEAddex Convenes Annual General Meeting 2023
04/5/202315:00GLOBEAddex Therapeutics to Release Q1 2023 Financial Results and..
05/4/202315:00GLOBEAddex Completes $5.0 Million Equity Financing
04/4/202315:00GLOBEAddex Publishes Dipraglurant Data Showing In Vivo Efficacy..
03/4/202315:00GLOBEAddex Raises $5.0 Million in Equity Financing
30/3/202316:00GLOBEAddex Reports Full Year 2022 Financial Results and Provides..
28/3/202316:00GLOBEAddex Therapeutics to Release Full-Year 2022 Financial..
16/3/202317:00GLOBEAddex Announces Upcoming Conferences it will participate for..
09/2/202317:00GLOBEAddex Regains Nasdaq Listing Compliance
06/2/202317:00GLOBEAddex Strategic Partner Completes Enrollment in ADX71149..
19/1/202317:00GLOBEAddex Provides Corporate Update and Financial Guidance

Your Recent History

NASDAQ
ADXN
Addex Therapeutics
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com